Jim Simons Synthetic Biologics, Inc. Transaction History

Renaissance Technologies LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$1.9 - $2.9 $212,040 - $323,640	111,600 Added 103.91%	219,000 $47,000
Q1 2022 May 13, 2022	BUY	$2.3 - $4.3 $199,639 - $373,240	86,800 Added 421.36%	107,400 $31,000
Q4 2021 Feb 11, 2022	BUY	$2.7 - $4.5 $55,620 - $92,700	20,600 New	20,600 $6,000
Q1 2021 May 13, 2021	SELL	$5.0 - $11.7 $6.19 Million - $14.5 Million	-1,237,733 Closed	0 $0
Q4 2020 Feb 10, 2021	BUY	$2.9 - $4.6 $1.1 Million - $1.74 Million	377,997 Added 43.97%	1,237,733 $474,000

Q3 2020 Nov 13, 2020	SELL	$4.5 - $7.1 $134,473 - $212,169	-29,883 Reduced 3.36%	859,736 $408,000
Q2 2020 Aug 13, 2020	BUY	$2.8 - $5.7 $562,520 - $1.15 Million	200,900 Added 29.17%	889,619 $455,000
Q1 2020 May 14, 2020	BUY	$2.7 - $6.1 $288,945 - $652,803	107,017 Added 18.4%	688,719 $221,000
Q4 2019 Feb 13, 2020	BUY	$3.9 - $5.3 $312,725 - $424,985	80,186 Added 15.99%	581,702 $295,000
Q3 2019 Nov 13, 2019	BUY	$3.9 - $5.9 $254,018 - $384,284	65,133 Added 14.93%	501,516 $228,000
Q2 2019 Aug 12, 2019	BUY	$4.9 - $6.6 $169,579 - $228,412	34,608 Added 8.61%	436,383 $240,000
Q1 2019 May 14, 2019	BUY	$5.9 - $8.1 $300,900 - $413,100	51,000 Added 14.54%	401,775 $273,000
Q4 2018 Feb 13, 2019	BUY	$5.2 - $26.8 $1.82 Million - $9.4 Million	350,775 New	350,775 $196,000

Ticker SYN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,844,100
Market Cap $9.51M
Description
Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.